Suncoast Clinical Research   Report issue

For profit Phase 2 Phase 3
Founded: New Port Richey FL United States (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2005
NCT00593905
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Suncoast Clinical Research, New Port Richey, Florida | Suncoast Lung Center | Suncoast Neuroscience

Active Ingredients

Drugs in Phase 3 Trials (1)

droxidopa (northera) (1 trial)

Drugs in Phase 2 Trials (2)

gly-230 (1 trial)

nb-001 (1 trial)

Drugs in Other Trials (3)

ambrisentan (letairis) (1 trial)

bosentan (tracleer) (1 trial)

sitaxentan (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autonomic Nervous System Diseases (Phase 3)

Diabetic Nephropathies (Phase 2)

Herpes Labialis (Phase 2)

Hypotension (Phase 3)

Hypotension, Orthostatic (Phase 3)

Pure Autonomic Failure (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 6